grant
Advanced Development of Patient Ascites Therapeutic Response Biosensors
Organization MASSACHUSETTS INSTITUTE OF TECHNOLOGYLocation CAMBRIDGE, UNITED STATESPosted 1 Mar 2025Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY2025AddressAdvanced DevelopmentAntibodiesApoptosisApoptosis PathwayAscitesAutomobile DrivingBasic Cancer ResearchBenign and Malignant Esophageal NeoplasmsBiodiversityBiologicalBiological DiversityBiopsyBiosensorBrightfield AnalysisBrightfield MicroscopyCarcinomatosisCell BodyCell DeathCellsCessation of lifeCharacteristicsClassificationClinicalClinical EvaluationClinical TestingCollectionCommunitiesCommunity HospitalsCytologyDeathDecision MakingDependenceDiagnosticDiseaseDisorderDrugsEquityEsophageal NeoplasiaEsophageal NeoplasmsEsophageal TumorEsophagus NeoplasmEsophagus TumorEvaluationFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryGastric NeoplasmsGastric TumorGenerationsGenomicsGenotypeGoalsHeterogeneityImmuneImmunesImmunotherapeutic agentIntratumoral heterogeneityInvestigatorsLabelLaboratoriesLiquid substanceMachine LearningMalignant CellMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryMeasurementMeasuresMedical centerMedicationMicroscopyMissionMolecularMorbidityMorbidity - disease rateMorphologyOvarianOvarian TumorOvary CancerOvary NeoplasmsOvary TumorPathway interactionsPatient CarePatient Care DeliveryPatientsPerformancePeritonealPharmaceutical PreparationsPhasePhenotypePopulationPre-clinical Drug Testing/DevelopmentPreclinical Drug DevelopmentPreclinical Drug Testing/DevelopmentProgrammed Cell DeathPublic HealthRefractory DiseaseRegimenReproducibilityResearchResearch PersonnelResearch SupportResearchersSamplingSeriesShippingSiteStomach NeoplasmsStomach TumorStromal CellsSupplementationSurvival RateSystematicsTechnologyTechnology AssessmentTemperatureTestingTherapeuticTherapeutic AgentsTherapeutic StudiesTherapy ResearchTimeTissue SampleTrainingValidationWorkabdominal dropsyapplied learningbiologicbiological sensorcancer cellcancer drug resistancecancer typecancers that are rarecare for patientscare of patientscaring for patientscell imagingcell typecellular imagingclinical practiceclinical relevanceclinical testclinically relevantcommercializationcommunity settingcompanion diagnosticscostdrivingdrug candidatedrug/agentesophagogastric cancerflow cytophotometryfluidgastroesophageal adenocarcinomagastroesophageal cancerhands-on learningheterogeneity in tumorshigh dimensionalityhydroperitoniahydrops abdominisimage guidanceimage guidedimmune drugsimmune-based therapeuticsimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentimprovedinteractive engagementinteractive learningintra-tumoral heterogeneityintratumor heterogeneityliquidmachine based learningmortalitynecrocytosisnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyovarian cancerovarian neoplasmpathwayperitoneal dropsyperitoneal exudatepre-clinicalpre-clinical drug developmentpreclinicalpreservationpreventpreventingrare cancerrare malignancyrare tumorresearch clinical testingresistance to cancer drugsresistant to cancer drugsresponseresponse to therapyresponse to treatmentsample collectionsingle cell technologyspecific biomarkersspecimen collectiontherapeutic candidatetherapeutic responsetherapy responsetranslational cancer researchtreatment responsetreatment responsivenesstumortumor heterogeneityvalidations
Description preview
PROJECT SUMMARY/ABSTRACT: Overcoming cancer drug resistance is a major unmet clinical need across
many cancer types, including difficult-to-treat diseases such as gastroesophageal (GEA) and ovarian cancer. In
principle, it should be possible to prioritize therapeutic regimen(s) given the molecular and cellular classification
of such tumors.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click